- 'Cancer of Fraud' Permeates Health Care System: Critics
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Judge Erases Couple's $525,000 Mortgage Payment
- Where Do Pardoned Turkeys Go?
- Foreign Demand Boosts US 7-Year Treasury Sale
- Google CEO Schmidt Makes Secret Visit to Iraq
- New-Home Sales Jump to Highest Level in Over a Year
- Consumers Catching the Holiday Spirit
- Jobless Claims Below 500,000, Durable Orders Slip
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- Oil Price to Average $75.40 in 2010: Poll
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Consumer Mood Improves, But Anxiety Over Personal Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- Foreign Demand Boosts US 7-Year Treasury Sale
- Mortgage Demand Slips as Rates Hold Near Lows
Text Size 
Investors could get good returns in the health-care sector and use it to protect themselves from wild price swings in other areas if they pick the right shares, despite the fact that many big-cap health-care stocks took a battering in 2007, Luis Correia, fund manager at Clariden Leu, told "Squawk Box Europe" Monday.
 |
AP |
Pharmacy benefit management companies, which are third-party administrators for drug programs, are a good bet, Correia said, because they benefit from the shift to generic drugs. Clariden Leu’s best performing fund in 2007 was focused on the growing generic sub-sector.
"Investors should not just play the sector by buying a few of the large-cap pharma stocks, they might again be disappointed," Correia said.
"They really need to look deeper into the sector, looking to sub-sectors like health-care services … the same is valid for medical technology and bio-technology," he added.
Watch for New Products
Correia said a rule of thumb was to look at new product cycles to decide which stocks would yield results.
"As long as companies are able to introduce new products … they will also deliver very interesting investment performances," he said.
Correia added that the health-care sector may face a possible setback if Barack Obama becomes the next U.S. president, because the Democrats have previously been vocal about reforming the Medicaid system and bringing down product prices.
"There is a certain risk, this is another reason why we need to be careful where we invest, we need to pick stocks which are less vulnerable on pricing pressure," he said.
Beaten-down large-cap pharma stocks such as the UK’s AstraZeneca could provide opportunities, because they are at very low valuations, Correia added: "The only way these stocks can go is up and the way they would go up by a positive surprise from their research and development effort."
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes